NCT05074940 · REGISTRY CONDITION SEARCH

Amivantamab in Adenoid Cystic Carcinoma

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE2
Status at capture: ACTIVE NOT RECRUITING
Registry last update: 2026-05-08

The purpose of the study is to determine if treatment with amivantamab will be efficacious in patients with recurrent and metastatic adenoid cystic carcinoma.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Overall Response Rate Measured by RECIST Criteria

→

outcome · POSTED

Progression Free Survival -Measured as Time of Treatment Allocation to Confirmed Progressive Disease or Death.

→

outcome · POSTED

Number of Participants With Adverse Events

→

outcome · POSTED

Number of Participants With a Genetic Mutation

→

outcome · POSTED

Quality of Life - Measured Via FACT-HN

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: 1. Pathologically or cytologically confirmed adenoid cystic carcinoma. Non-salivary gland primary sites are allowed. 2. Recurrent and/or metastatic disease not amenable to other curative intent therapy. Patients must have had evidence of progressive disease by RECIST v1.1 within 6 months of study enrollment. 3. Presence of measurable disease as defined by RECIST v1.1 4. Age ≥18 years. 5. ECOG performance status, see Appendix A). 6. Patients must have adequate organ and marrow function 7. Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression in the last 4weeks. 8. Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy. 9. Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. 10. Before enrollment, a participant must be (as defined in Appendix 2: Contraceptive Guidance and Collection of Pregnancy Information) 11. A participant of childbearing potential must have a negative serum (b-human chorionic gonadotropin \[b-hCG\]) at screening and within 72 hours of the first dose of study treatment and must agree to further serum or urine pregnancy tests during the study. 12. A participant must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study and for 6 months after receiving the last dose of study drug. 13. A participant must wear a condom when engaging in any activity that allows for passage of ejaculate to another person during the study and for 6 months after receiving the last dose of study treatment. A participant who is sexually active with a partner of childbearing potential must agree to use a condom with spermicidal foam/gel/film/cream/suppository and his partner must also be practicing a highly effective method of contraception (i.e., established use of oral, injected or implanted hormonal methods of contraception; placement of an intrauterine device \[IUD\] or intrauterine system \[IUS\]). If the subject is vasectomized, they must still use a condom (with or without spermicide) for prevention of passage of exposure through ejaculation, but their partner is not required to use contraception. 14. The subject must also not donate sperm during the study and for 6 months after receiving the last dose of study drug. 15. Ability to understand and the willingness to sign a written informed consent document. 16. Participant must be willing and able to adhere to the lifestyle restrictions specified in this protocol. Exclusion Criteria 1. History of allergy or intolerance to study drug components. 2. Prior use of amivantamab. 3 .Patients who have had chemotherapy or immunotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study. Palliative radiotherapy is allowed and does not require washout as long as it does not include a target lesion. 4\. Positive hepatitis B (hepatitis B virus \[HBV\]) surface antigen (HBsAg) Note: Subjects with a prior history of HBV demonstrated by positive hepatitis B core antibody are eligible if they have at Screening 1) a negative HBsAg and 2) a HBV DNA (viral load) below the lower limit of quantification, per local testing. Subjects with a positive HBsAg due to recent vaccination are eligible if HBV DNA (viral load) is below the lower limit of quantification, per local testing. 5\. Positive hepatitis C antibody (anti-HCV). Note: Subjects with a prior history of HCV, who have completed antiviral treatment and have subsequently documented HCV RNA below the lower limit of quantification per local testing are eligible. 6.Participant is positive for human immunodeficiency virus (HIV), with 1 or more of the following: 1. Receiving ART that may interfere with study treatment (consult sponsor for review of medication prior to enrollment) 2. CD4 count \<350 at screening 3. AIDS-defining opportunistic infection within 6 months of start of screening 4. Not agreeing to start ART and be on ART\>4 weeks plus having HIV viral load\<400 copies/mL at end of 4-week period (to ensure ART is tolerated and HIV controlled). 7.Other clinically active infectious liver disease. 8\. Participant has active cardiovascular disease including, but not limited to: * A medical history of deep vein thrombosis or pulmonary embolism within 1 month prior to enrollment or any of the following within 6 months prior to enrollment: myocardial infarction, unstable angina, stroke, transient ischemic attack, coronary/peripheral artery bypass graft, or any acute coronary syndrome. Clinically non-significant thrombosis, such as non-obstructive catheter-associated thrombus(clots), or incidental or asymptomatic pulmonary embolism are not exclusionary. * Participant has a significant genetic predisposition to venous thromboembolic(VTE) events such as Factor V Leiden. * Participant has a prior history of VTE and is not on appropriate therapeutic anticoagulation as per NCCN or local guidelines. * Uncontrolled (persistent) hypertension: systolic blood pressure \>160 mm Hg;diastolic blood pressure \>100 mm Hg. * Congestive heart failure (CHF), defined as New York Heart Association (NYHA)class III-IV or hospitalization for CHF (any NYHA class; refer to Appendix 3:New York Heart Association Criteria) within 6 months of starting drug. 9\. Subject has uncontrolled illness, including but not limited to: * Uncontrolled diabetes * Ongoing or active infection (includes infection requiring treatment with antimicrobial therapy \[participants will be required to complete antibiotics 1 week prior to starting study treatment\] or diagnosed or suspected viral infection). * Active bleeding diathesis * Impaired oxygenation requiring continuous oxygen supplementation (e.g., due to medical condition requiring chronic continuous oxygen therapy). * Psychiatric illness/social situation that would limit compliance with study requirements. * Any ophthalmologic condition that is clinically unstable 10\. Active or past medical history of Interstitial lung disease (ILD)/pneumonitis, including drug-induced or radiation ILD/ pneumonitis. 11\. Participant had major surgery excluding placement of vascular access or tumor biopsy or had significant traumatic injury within 4 weeks before enrollment, or will not have fully recovered from surgery, or has surgery planned during the time the participant is expected to participate in the study. Note: Participants with planned surgical procedures to be conducted under local anesthesia may participate. 12\. Immune-mediated rash from checkpoint inhibitors that has not resolved prior to enrollment. 13\. Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities \> Grade 1) with the exception of alopecia or Grade 2 neuropathy. 14\. Patients who are receiving any other investigational agents. Patients who have received other investigational agents previously who are no longer receiving these investigational agents may be eligible at the discretion of the PI. A 30 day washout from last dose of previous anticancer drug is required. 15\. Pregnant women are excluded from this study. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with breastfeeding should be discontinued if the mother is treated with amivantamab. 16\. Judgment by the investigator that the patient is unsuitable to participate in the study and the patient is unlikely to comply with study procedures, restrictions, and requirements.
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Amivantamab weekly for the first cycle and biweekly thereafter.
intervention Names
Drug: Amivantamab
label
Amivantamab
type
EXPERIMENTAL

interventions

arm Group Labels
Amivantamab
description
Patients will receive amivantamab at 1050mg weekly for the first cycle and biweekly thereafter (1400mg for patients ≥80kg).
name
Amivantamab
type
DRUG

Study design

allocation

intervention Model

SINGLE_GROUP

intervention Model Description

Open-label phase II single arm trial

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 21
type: ACTUAL

Registered outcome plans (not posted results)

other Outcomes

description
To determine the molecular signatures of response and resistance to amivantamab via molecular signatures of response and resistance- measured by comprehensive analysis of Transcriptome Sequencing
measure
Number of Participants With a Genetic Mutation
time Frame
2 years
description
The FACT HN is a patient reported outcome (PRO) measure that assesses health related quality of life in patients with head and neck cancer. It evaluates general cancer related quality of life as well as symptoms and concerns specific to head and neck cancer. The total score range is 0 - 144, with higher scores reflecting more positive perceptions across areas of well-being. A difference score from end of treatment and pre-treatment was calculated.
measure
Quality of Life - Measured Via FACT-HN
time Frame
2 years

primary Outcomes

description
To determine the overall response rate in patients with recurrent and metastatic adenoid cystic carcinoma treated with amivantamab. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR."
measure
Overall Response Rate Measured by RECIST Criteria
time Frame
2 years

secondary Outcomes

description
To determine the progression free survival with recurrent and metastatic adenoid cystic carcinoma treated with amivantamab.
measure
Progression Free Survival -Measured as Time of Treatment Allocation to Confirmed Progressive Disease or Death.
time Frame
Up to 27 months
description
To determine safety of amivantamab in patients with recurrent and metastatic adenoid cystic carcinoma as measured by CTCAE v5. Any subject that had at least one adverse event will be counted.
measure
Number of Participants With Adverse Events
time Frame
Up to 16 months regardless of attribution should be collected continuously during the treatment period and for a minimum of 30 days following the last dose of study treatment.

Full study description

brief Summary: The purpose of the study is to determine if treatment with amivantamab will be efficacious in patients with recurrent and metastatic adenoid cystic carcinoma.
detailed Description: ACC is a rare cancer of salivary glands and other glandular tissue. It is slow growing and is usually treated with surgery and radiation. However, this type of cancer tends to have a high rate of recurrence and metastatic spread, which develops over several years. We hypothesize that amivantamab, a bispecific EGFR and MET inhibitor will be efficacious in ACC. Patients will receive amivantamab at 1050mg weekly for the first cycle and biweekly thereafter (1400mg for patients ≥80kg).

Source references

references

citation
Hanna GJ, Zamulko OY, Grover P, Adkins DR, Oppelt PJ, Romano AE, Lehn MA, Bachmann LM, Wikenheiser-Brokamp KA, Lemmon CA, Forsythe AJ, Allen CL, Pan J, Rai SN, El-Gamal D, Wise-Draper TM. Amivantamab for Recurrent or Metastatic Adenoid Cystic Carcinoma: A Phase 2 Nonrandomized Clinical Trial. JAMA Otolaryngol Head Neck Surg. 2026 Apr 1;152(4):376-383. doi: 10.1001/jamaoto.2025.5404.
pmid
41746627
type
DERIVED

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-013918c8eb45995e0eae
requested nct id
NCT05074940
primary nct id
NCT05074940
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Salivary+Gland+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
38e97f6c23d7b292911d062dea3fc0dffbdcbde03aae232fe8d067fdd28034c9
payload sha256
4628a75d3a8124545b5c035e3b441e748b9c9856aec704fa18260cbc89dc279b
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-013918c8eb45995e0eae
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT05074940
occurrences
context exact
NCT05074940
end
11
exact text
NCT05074940
start
0
offset unit
unicode_code_points
query cond
Salivary Gland Cancer
query disease state id
ds-salivary-gland-cancer
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-salivary-gland-cancer-000.json
source file sha256
38e97f6c23d7b292911d062dea3fc0dffbdcbde03aae232fe8d067fdd28034c9
source json pointer
/studies/49/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
045a270582e4e7befb9fe1eb0951f2e4325ac88d2f5a8f76f77b89e1a418dc23
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Salivary+Gland+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice